Photodermatit developed with pirfenidone treatment in patient diagnosed with IPF

Abstract

Idiopathic pulmonary fibrosis (IPF) is the most common of the major idiopathic interstitial pneumonia (IIP) of unknown etiology, often presenting in advanced age, limited to the lungs, characterized by histopathologically and/or radiologically usual interstitial pneumonia (UIP) pattern, and progressing with chronic, progressive fibrosis. is the most common form. Since IPF is a disease with irreversible fibrosis, there is no curative treatment except lung transplantation. The aim of the treatments given is to stop the progression of the disease, to prevent exacerbations and to prolong the survival time. The greatest improvement in the treatment of IPF in recent years has been the use of antifibrotic drugs (Pirfenidone and nintedanib) that prevent fibrosis developing in the lung parenchyma. In this case, we aimed to present the side effect of photodermatitis in a patient who applied to our outpatient clinic with complaints of shortness of breath and cough for many years and was diagnosed with IPF and started on pirfenidone treatment.